<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303431</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-A-U157</org_study_id>
    <secondary_id>2015-005732-18</secondary_id>
    <nct_id>NCT02303431</nct_id>
  </id_info>
  <brief_title>Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study</brief_title>
  <official_title>A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a
      single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy
      to see what the body does to the drug (pharmacokinetics) and what the drug does to the body
      (pharmacodynamics), and to compare if these effects are similar to those observed in adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, open-label, multiple-center study in pediatric patients from 0 to &lt; 18 years of age.
      Patients will receive a single dose of edoxaban to match either the 30 mg (low dose) or the
      60 mg (high dose) exposure in adults. Exact doses will be selected during the study on the
      basis of PK modeling of emerging data. If unanticipated exposures are observed, the target
      doses may be modified to best match expected exposure response relationships observed in
      adults.

      Enrollment in the study will start with the low dose, highest age group (adolescents) and
      will continue from low to high dose in each age group and from higher to lower age groups.
      Enrollment in the next dose/age cohort will begin after 50% of the subjects have completed
      the previous dose/age cohort.

      Age cohorts and dose groups: (6 participants each in low and high dose groups, for a total of
      12 participants per age cohort)

        -  12 to &lt; 18 years of age

        -  6 to &lt;12 years of age

        -  2 to &lt;6 years of age

        -  6 months to &lt;2 years of age

        -  0 to &lt;6 months of age
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK)- Apparent systemic clearance (CL/F)</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Apparent volume of distribution (V/F)</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Area under the concentration-time curve (AUC) for edoxaban and metabolites</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings); metabolites include D21-2393, D21-3231, D21-1402, and D21-2135</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK- Metabolite/parent ratios for AUC</measure>
    <time_frame>within 36 hours postdose</time_frame>
    <description>A sampling windows approach will be used: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 5 blood samplings); metabolites include D21-2393, D21-3231, D21-1402, and D21-2135</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PDy)- Mean prothrombin time (PT)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDy- Mean activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDy- Mean anti-Factor Xa (FXa)</measure>
    <time_frame>Predose and within 36 hours postdose</time_frame>
    <description>Predose and immediately after simultaneously scheduled PK blood samples, using a dosing windows approach: 0.25 to 1, 1.5 to 3, 4 to 8, 9 to 14, and 24 to 36 hours postdose (total of 6 blood samplings)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety- Number of participants with clinically significant changes in safety assessments</measure>
    <time_frame>Predose to Day 10</time_frame>
    <description>Safety assessments: adverse events, physical examination findings, vital signs, clinical laboratory assessments, and urinalysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean palatability score for the liquid formulation on a 100 mm visual analog scale (VAS)</measure>
    <time_frame>within 30 minutes after dosing</time_frame>
    <description>Bitterness, sweetness, and overall taste or aroma will be assessed by participants receiving the liquid oral suspension or their guardians using visual analog scale (VAS) scores</description>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to &lt; 18 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 to &lt; 18 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to &lt; 12 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 to &lt; 12 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 to &lt; 6 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 to &lt; 6 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months to &lt;2 years of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months to &lt;2 years of age: edoxaban high dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 to 6 months of age: edoxaban low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0 to 6 months: edoxaban high dose group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban low dose</intervention_name>
    <description>Edoxaban low dose</description>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_label>Cohort 3a</arm_group_label>
    <arm_group_label>Cohort 4a</arm_group_label>
    <arm_group_label>Cohort 5a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban high dose</intervention_name>
    <description>Edoxaban high dose</description>
    <arm_group_label>Cohort 1b</arm_group_label>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_label>Cohort 3b</arm_group_label>
    <arm_group_label>Cohort 4b</arm_group_label>
    <arm_group_label>Cohort 5b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a pediatric subject requiring anticoagulant therapy

          -  Will abstain from the use of nonsteroidal anti-inflammatory drugs (such as ibuprofen),
             and other antiplatelet and anticoagulant agents (except for aspirin) from 24 hours
             prior to edoxaban dose until after the last PK sample is collected

          -  Will follow food and concomitant medication restrictions

        Exclusion Criteria:

          -  Any major or clinically relevant unexplained bleeding during prior anticoagulant
             therapy

          -  History of abnormal bleeding or coagulation within last 6 months prior to study drug
             administration

          -  Renal function with glomerular filtration rate (GFR) less than 50% of normal for age
             and size

          -  Malabsorption disorders (e.g., cystic fibrosis or short bowel syndrome)

          -  Hepatic disease associated with coagulopathy leading to a clinically relevant bleeding
             risk, alanine transaminase (ALT) &gt; 5 times the upper limit of normal (ULN) or total
             bilirubin &gt; 2 times the ULN with direct bilirubin &gt; 20% of the total
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>310-825-0867</phone>
      <email>GRoach@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>650-497-8953</phone>
      <email>mjeng@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>303-724-0365</phone>
      <email>Michael.wang@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>904-697-3789</phone>
      <email>Cynthia.Gauger@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>312-227-1549</phone>
      <email>bradley.marino@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia and Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>317-871-0000</phone>
      <email>sgupta@ihtc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville ; Kosair Charities Pediatric Clincial Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>502-629-5830</phone>
      <email>sully@louisville.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (DUMC)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center - Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>215-590-4040</phone>
      <email>RossanoJ@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hasbro Children's Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>401-444-5171</phone>
      <email>trenaud@lifespan.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>901-595-4753</phone>
      <email>Ulrike.Reiss@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>414-266-1777</phone>
      <email>rniebler@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>905-599-3326</phone>
      <email>bhattm2@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+33 557656465</phone>
      <email>jean-benoit.thambo@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini - UOSD Emostasi e Trombosi</name>
      <address>
        <city>Genova</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 0105636709</phone>
      <email>aclaudiomolinari@ospedale-gaslini.ge.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>A O Universita degli Studi di Padova ; Dipartimento di Salute della Donna e del Bambino-Universita di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 0498213502</phone>
      <email>ornella.milanesi@unipd.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Hospital</name>
      <address>
        <city>Rome</city>
        <zip>165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 0668592579</phone>
      <email>antonella.santilli@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital</name>
      <address>
        <city>Irbid</city>
        <zip>22110</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+962 2 709 5777</phone>
      <email>dima@just.edu.jo</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 932746000</phone>
      <email>parosanta@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 655667830</phone>
      <email>mariaa.tejero.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 913303413</phone>
      <email>Emilio.vargas@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 912071466</phone>
      <email>a.borobia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba</name>
      <address>
        <city>Vitoria Gasteiz</city>
        <zip>01010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 619845144</phone>
      <email>ignacio.diezlopez@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 1133928184</phone>
      <email>john.thomson8@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 2071887545</phone>
      <email>jayanthi.alamelu@gstt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 2073518296</phone>
      <email>Zdenek.Slavik@rbht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 2381206724</phone>
      <email>Tara.Bharucha@uhs.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Jordan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Egypt</country>
    <country>Lebanon</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Pharmacokinetics (PK)</keyword>
  <keyword>Pharmacodynamics (PDy)</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

